Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...

Warburg Pincus has committed to invest CDN$35 million in Protox, which develops receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer. Warburg is a global PE firm.

VANCOUVER, Oct. 8 /CNW/ - Protox Therapeutics Inc. (TSX: PRX - News), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its Phase 1 study of ...

Protox Therapeutics Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease VANCOUVER, April 29 /CNW/ - Protox ...

Warburg Pincus to become co's largest shareholder Says to finance clinical activities for BPH treatment Protox shares up 14 pct Warburg Pincus members to assume Protox chairmanship Sept 29 (Reuters) - ...

Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...

Protox announced on the 14th that it received export approval for its botulinum toxin product, Protoxin Injection, from the Ministry of Food and Drug Safety on the 13th. Botulinum toxin is a toxin ...

VANCOUVER, Aug. 11 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended ...

VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...

Last month, the British Association of Plastic Surgeons revealed that cosmetic surgery is down 40 per cent. But it could be that people are turning towards non-surgical options, such as Botox - it ...